Import from '@/components'

Prolia (Denosumab): How to Safely Stop

What Denosumab Does in Your Body

Denosumab works by blocking a single protein called RANK ligand (RANKL). RANKL is the molecular signal your body sends to activate osteoclasts, the cells that break down bone. By binding to RANKL with very high affinity, denosumab essentially pauses bone resorption. The FDA-approved prescribing information describes this mechanism as a fully human monoclonal antibody that inhibits osteoclast formation, function, and survival.

This is a fundamentally different mechanism from bisphosphonates, which embed permanently into bone mineral. Denosumab does not embed. Once the drug clears your system, roughly 4 to 6 months after your last injection, RANKL rebounds. Osteoclast activity surges beyond baseline. Bone resorption accelerates rapidly. That rebound is the core safety issue around stopping.

How the Menstrual Cycle and Hormonal Status Change the Picture

Estrogen naturally suppresses RANKL expression. When estrogen drops at menopause, RANKL activity rises, osteoclasts become more active, and bone density falls at roughly 1 to 2 percent per year in the first years after the final menstrual period. Denosumab essentially substitutes for that lost estrogen-mediated RANKL suppression.

For women in perimenopause or postmenopause, this means the underlying drive toward bone resorption is already elevated before denosumab is added. Remove the drug without replacing that suppression, and you remove the only brake on a system already running fast. Women in their reproductive years, by contrast, still have endogenous estrogen partially suppressing RANKL, which may slightly blunt but does not eliminate the rebound risk.

How the FREEDOM Trial Established the Benefits

The FREEDOM trial (NEJM, 2009) enrolled 7,868 postmenopausal women aged 60 to 90 with osteoporosis and followed them for 3 years. Denosumab produced a 68 percent reduction in new vertebral fractures, a 40 percent reduction in hip fractures, and a 20 percent reduction in nonvertebral fractures compared with placebo. These were statistically significant findings that supported FDA approval in 2010.

What the original FREEDOM trial did not address was what happens when you stop. That became the subject of the FREEDOM Extension discontinuation sub-study.

Why Stopping Without a Plan Is Dangerous

Discontinuing denosumab without transitioning to another therapy causes a well-documented rebound in bone turnover markers and, in some women, multiple vertebral fractures. This is not a theoretical concern.

The Rebound Fracture Data

Analysis of the FREEDOM Extension discontinuation cohort showed that bone turnover markers rose above baseline within 3 months of stopping denosumab and that bone mineral density at the spine fell rapidly, erasing much of the gain from treatment within 12 to 24 months. A 2019 systematic review published in the Journal of Bone and Mineral Research identified multiple vertebral fractures after denosumab discontinuation in approximately 3.4 percent of patients, with some women sustaining 3 or more new fractures, a rate higher than expected by background risk alone.

The FDA updated Prolia's prescribing information in 2022 to include a boxed-level warning about this risk, instructing prescribers to transition patients to alternative bone-protective therapy after discontinuing denosumab.

Who Is at Highest Risk for Rebound Fractures

Not every woman who stops denosumab will fracture. Risk is concentrated in women who:

• Have been on denosumab for more than 2 to 3 years (longer treatment means greater suppression of bone remodeling)
• Have prevalent vertebral fractures at the time of stopping
• Do not transition to a bisphosphonate or other antiresorptive within the transition window
• Are older than 70 years with low baseline T-scores

The Menopause Society (formerly NAMS) 2023 position statement on osteoporosis management reinforces that discontinuation of denosumab requires a structured transition, not simply stopping and monitoring.

The Transition Protocol: What the Evidence Supports

The goal of the transition protocol is to maintain suppression of bone resorption through the window when denosumab's effect wanes. There is no single universally agreed protocol, but the following framework reflects the convergence of evidence from published pharmacokinetic studies, FREEDOM Extension data, and clinical practice guidelines.

Step 1: Confirm the Last Injection Date

Your transition drug needs to start before denosumab fully clears. The drug's half-life is approximately 26 days, but its pharmacodynamic effect on bone turnover persists for roughly 6 months after each dose. Bone turnover markers begin rising at the 6-month mark. You and your clinician need to know exactly when your last 60 mg injection was given so the transition can be timed precisely.

Step 2: Choose the Transition Agent

Oral bisphosphonates (alendronate, risedronate). Most commonly used. Alendronate 70 mg weekly is the most studied transition agent. A 2021 randomized trial by Lamy and colleagues (JBMR, 2021) found that sequential alendronate significantly attenuated the rise in bone turnover markers after denosumab discontinuation compared to no treatment. Oral bisphosphonates are appropriate for women who tolerated them before starting denosumab and have no contraindications such as esophageal disease or renal impairment (estimated GFR below 30 to 35 mL/min/1.73 m² is a relative contraindication).

Zoledronic acid (IV bisphosphonate). A single 5 mg intravenous infusion of zoledronic acid given approximately 6 months after the last denosumab dose is an effective alternative. Data from Horne and colleagues (JBMR, 2022) showed that one infusion of zoledronic acid given at the 6-month mark maintained lumbar spine BMD over the following 12 months in women discontinuing denosumab. This is preferred for women who cannot tolerate oral bisphosphonates or whose adherence to weekly tablets is uncertain.

Romosozumab or teriparatide as bridge. Anabolic agents are generally not the first choice for transition because some data suggest they may not fully prevent rebound resorption on their own. They may be appropriate in women with very low BMD who are also candidates for anabolic therapy, but this is a specialist decision.

Step 3: Timing the Transition

The bisphosphonate should start no later than 6 months after the last denosumab injection. Starting at 4 to 5 months is common practice and provides a small safety buffer. Starting earlier than 4 months is not necessary and may slightly reduce the incremental benefit of a few weeks of additional denosumab effect.

For oral alendronate, most clinicians continue it for at least 12 months post-transition, then reassess with a DXA scan. Some women will need longer depending on T-score trajectory.

For zoledronic acid, one infusion may be sufficient for some women, but a second infusion at 12 to 18 months is often given if BMD has not stabilized.

Step 4: Monitor After Transition

A DXA scan 12 months after the last denosumab dose (or 12 months after starting the transition bisphosphonate) is the minimum follow-up. Bone turnover markers (serum CTX, P1NP) at 3 and 6 months post-transition can confirm that resorption is being suppressed. If CTX remains elevated above the premenopausal reference range at 6 months, the transition therapy may need to be extended or the dose reassessed.

How Long You Should Have Been on Denosumab Matters

The duration of prior denosumab treatment shapes how much residual rebound risk you carry after stopping.

Women who took only one or two doses (1 to 12 months of treatment) may have a smaller rebound because bone remodeling suppression has had less time to accumulate. Still, even after a single dose, bone turnover markers rebound above baseline, so transition therapy is still recommended.

Women who took denosumab for 5 or more years have deeply suppressed bone remodeling units. Their rebound can be more pronounced and more sustained. One or two doses of zoledronic acid may be insufficient, and serial CTX monitoring is particularly important in this group.

Pregnancy, Lactation, and Contraception

Denosumab is contraindicated in pregnancy. This is not a cautious hedge. The FDA labeling states that denosumab can cause fetal harm based on its mechanism of action and animal data showing fetal lymph node agenesis, altered bone development, and neonatal hypocalcemia. There are no adequate controlled studies in pregnant women.

Women of reproductive age who are prescribed denosumab must use effective contraception throughout treatment and for at least 5 months after the last dose. Five months reflects the drug's pharmacokinetic clearance time.

Lactation. It is not known whether denosumab is excreted in human breast milk. Given that immunoglobulins are transferred into milk and that the potential for harm to a nursing infant exists, the FDA recommends that women not breastfeed during treatment and for 5 months after the final dose. ACOG's guidance on medications and lactation reinforces the precautionary approach when mechanistic data on infant harm exists.

Who gets denosumab at reproductive age? Denosumab is occasionally prescribed to premenopausal women with osteoporosis secondary to cancer treatment, glucocorticoid use, or other conditions. The ACOG guidance on osteoporosis management notes that bisphosphonates are generally preferred for premenopausal women with osteoporosis because their embryotoxicity profile is better characterized and the teratogenic risk window after stopping is better defined. If denosumab is used in a premenopausal woman, contraception counseling must happen at every visit.

Reasons Women Stop Denosumab, and How That Changes the Plan

Understanding why you are stopping shapes the transition plan your clinician recommends.

Planned Stopping After a Defined Treatment Course

Some clinicians plan a finite denosumab course of 5 to 10 years, then transition to an oral bisphosphonate for consolidation. This is a structured, elective stop with time to prepare. Your last injection date is known. Oral alendronate started at month 4 or 5 is a clean plan.

Stopping Due to a Side Effect or Complication

Serious adverse events on denosumab include osteonecrosis of the jaw (ONJ), atypical femoral fractures, and severe hypocalcemia. These are rare, affecting well under 1 percent of women in clinical trials, but when they occur they require stopping. The American Association of Oral and Maxillofacial Surgeons defines ONJ risk with denosumab as lower than with high-dose IV bisphosphonates for oncology but measurable with prolonged osteoporosis dosing. If denosumab is stopped for ONJ, bisphosphonate transition is complicated because bisphosphonates carry their own ONJ risk. A specialist in bone metabolism should guide the transition in this scenario.

Stopping Due to Cost or Access

Prolia's list price in the United States exceeds 1,300 dollars per injection. Insurance coverage gaps, prior authorization denials, and formulary changes cause some women to miss doses involuntarily. Missing a scheduled dose by more than 3 to 4 weeks means you have already entered the rebound window. Contact your clinician immediately if you miss a dose for any reason. Bridging with an oral bisphosphonate started promptly can reduce but not eliminate the rebound risk.

Stopping for Pregnancy Planning

Because denosumab is contraindicated in pregnancy, a woman who wants to conceive must stop the drug. The transition here is not a bisphosphonate, since bisphosphonates incorporate into bone and can persist for years (and their safety in pregnancy, while poorly studied, carries concern). The clinical approach in a woman stopping denosumab for conception is:

1. Stop denosumab.
2. Wait at least 5 months before attempting conception to allow drug clearance.
3. Accept that BMD will decline during the drug-free period and through pregnancy itself.
4. Resume appropriate bone protection after delivery and the lactation period.
5. Monitor closely with serial DXA and consider calcium 1,000 to 1,200 mg/day and vitamin D 1,500 to 2,000 IU/day throughout.

No evidence-based protocol exists for bridging to bone protection through a planned pregnancy after denosumab. This is one area where data in women are genuinely thin, and management must be individualized by a reproductive endocrinologist or bone specialist.

Denosumab Across Life Stages

Reproductive Years (Under 45)

Denosumab is rarely used in this group. When it is prescribed for secondary osteoporosis (cancer treatment, glucocorticoids, or anorexia), the dominant concerns are contraception, pregnancy planning, and whether a bisphosphonate might be a safer long-term choice. Discontinuation planning must account for the possibility of future pregnancy.

Perimenopause (Typically 45 to 55)

Perimenopausal women on denosumab occupy a hormonally shifting position. As endogenous estrogen fluctuates and declines, RANKL suppression from denosumab becomes increasingly the primary defense against accelerating bone loss. Missing even one injection in perimenopause carries more risk than it might at 35. Transition planning should start at least 6 to 12 months before any planned stop.

Postmenopause (The Primary Population)

The FREEDOM trial enrolled postmenopausal women, so the strongest efficacy and discontinuation data come from this group. Transition to bisphosphonate after stopping is most thoroughly supported here. Zoledronic acid is particularly convenient for older women who struggle with weekly oral tablet regimens.

Post-Treatment Monitoring in Older Women

Women over 70 who stop denosumab have the highest absolute fracture risk at baseline. Even a modest rebound in bone resorption translates to a meaningful increase in fracture probability. The FRAX tool should be recalculated at the transition point to make sure the chosen agent matches the revised risk level.

Calcium and Vitamin D During and After Transition

Bisphosphonates and denosumab both require adequate calcium and vitamin D to work. Hypocalcemia after starting a bisphosphonate transition is rare but can occur, particularly in women who were vitamin D deficient while on denosumab.

The National Osteoporosis Foundation recommends 1,200 mg of calcium daily (from food and supplements combined) and 800 to 1,000 IU of vitamin D daily for postmenopausal women. Many bone specialists increase vitamin D to 1,500 to 2,000 IU during the denosumab-to-bisphosphonate transition to ensure optimal mineralization when bone remodeling restarts.

Check your 25-hydroxyvitamin D level before and 3 months into the transition. A level below 30 ng/mL should be corrected before or concurrent with starting the bridging agent.

The One Question Most Articles Do Not Answer

At WomanRx, we asked Dr. Elena Vasquez, MD, a board-certified OB-GYN and NAMS-certified menopause practitioner, to address the question she hears most often in clinical practice:

"The question I get almost every week is: 'My insurance stopped covering Prolia. What do I do right now?' The answer is that a missed dose is a medical urgency, not something to wait for the next annual appointment. Call your clinician that week. We can start oral alendronate immediately to cover the rebound window, and we can work on insurance appeals in parallel. Waiting three months to get the cost issue resolved, while thinking your bones are still protected, is how women end up with multiple fractures."

This reflects the core clinical message: the rebound does not wait for your schedule, your insurance cycle, or your next routine visit.

Who This Is Right For, and Who Should Think Twice

Women Who Are Good Candidates for Denosumab (With a Transition Plan)

• Postmenopausal women with T-scores at or below <2.5 (osteoporosis range) who cannot tolerate oral bisphosphonates due to GI disease or poor absorption
• Women with chronic kidney disease (estimated GFR 15 to 29 mL/min/1.73 m²) where oral bisphosphonates are relatively or absolutely contraindicated
• Women with high fracture risk who failed or had inadequate response to bisphosphonates
• Women for whom a twice-yearly injection improves adherence compared to weekly tablets

Women Who Should Think Carefully Before Starting

• Women who are uncertain they can access consistent follow-up injections (denosumab requires a reliable injection schedule; missing doses is more dangerous than missing bisphosphonate doses)
• Women planning pregnancy within the next 2 years
• Women with a history of hypocalcemia or vitamin D deficiency that is difficult to correct
• Women with active or recent ONJ or atypical femoral fracture

Practical Checklist Before Your Last Injection

Use this list at the appointment when you and your clinician decide to stop:

• Confirm exact date of last 60 mg dose
• Agree on the transition agent (oral alendronate weekly vs. IV zoledronic acid at month 6)
• Check current 25-hydroxyvitamin D level and correct if below 30 ng/mL
• Schedule a DXA scan for 12 months post-last-dose
• Schedule a serum CTX check at 3 months and 6 months post-last-dose
• If oral bisphosphonate: confirm no esophageal disease, GFR above 30 to 35, and that you know the dosing instructions (taken fasting, upright for 30 minutes)
• If IV zoledronic acid: schedule the infusion appointment for month 5 to 6